• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项前瞻性药物安全性研究结果显示,辛伐他汀不会引起晶状体改变。

No lens changes caused by simvastatin results from a prospective drug safety study.

作者信息

Schmidt J, Schmitt C, Hockwin O

机构信息

Department of Experimental Ophthalmology, University of Bonn, FRG.

出版信息

Lens Eye Toxic Res. 1990;7(3-4):643-50.

PMID:2100182
Abstract

45 patients suffering from a primary hypercholesterolemia were treated with Simvastatin. Additionally to internal visits regular ophthalmologic examinations were performed. The main interest concerning the ophthalmologic examination was directed toward the documentation and measurement of lens opacities by means of Scheimpflug photography. Moreover, every 6 months a complete regular ophthalmologic examination was carried out. We present the results after a time period of 2 years. Relevant changes in clinical findings could not be found. In some patients the Scheimpflug measurement revealed an increase in light scattering. These findings, however, were within the limit of normal age related changes.

摘要

45名原发性高胆固醇血症患者接受了辛伐他汀治疗。除了门诊就诊外,还定期进行眼科检查。眼科检查的主要关注点是通过Scheimpflug摄影记录和测量晶状体混浊情况。此外,每6个月进行一次全面的常规眼科检查。我们呈现了2年时间段后的结果。未发现临床检查结果有相关变化。在一些患者中,Scheimpflug测量显示光散射增加。然而,这些发现属于正常年龄相关变化的范围。

相似文献

1
No lens changes caused by simvastatin results from a prospective drug safety study.一项前瞻性药物安全性研究结果显示,辛伐他汀不会引起晶状体改变。
Lens Eye Toxic Res. 1990;7(3-4):643-50.
2
Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin.使用HMG-CoA还原酶抑制剂普伐他汀的眼部药物安全性研究。
Lens Eye Toxic Res. 1990;7(3-4):631-42.
3
[The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Fortschr Ophthalmol. 1991;88(6):843-5.
4
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂辛伐他汀与人类晶状体。3年随访的临床结果。
Arzneimittelforschung. 1992 Aug;42(8):1023-4.
5
Ocular drug safety and HMG-CoA-reductase inhibitors.眼部药物安全性与HMG-CoA还原酶抑制剂
Ophthalmic Res. 1994;26(6):352-60. doi: 10.1159/000267501.
6
[Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].[辛伐他汀治疗中重度高胆固醇血症患者的有效性和耐受性。一项为期12个月的研究结果]
Minerva Cardioangiol. 1993 Mar;41(3):105-9.
7
[Absence of cataractogenic effect of lovastatin (Mevinacor) so far].[目前洛伐他汀(美降脂)无致白内障作用]
Fortschr Ophthalmol. 1991;88(5):431-3.
8
Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.降脂药物辛伐他汀的眼部副作用?一年随访。
Lens Eye Toxic Res. 1989;6(1-2):331-7.
9
[Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].心脏移植后高胆固醇血症的治疗:长期随访中使用HMG-CoA还原酶抑制剂辛伐他汀的疗效
Z Kardiol. 1995 Feb;84(2):130-6.
10
[Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].[辛伐他汀治疗原发性高胆固醇血症三年的耐受性、疗效及安全性评估]
Schweiz Med Wochenschr. 1990 Jan 27;120(4):85-91.

引用本文的文献

1
Cholesterol Bilayer Domains in the Eye Lens Health: A Review.眼晶状体健康中的胆固醇双层结构域:综述
Cell Biochem Biophys. 2017 Dec;75(3-4):387-398. doi: 10.1007/s12013-017-0812-7. Epub 2017 Jun 29.
2
Comparative tolerability of the HMG-CoA reductase inhibitors.HMG-CoA还原酶抑制剂的耐受性比较
Drug Saf. 2000 Sep;23(3):197-213. doi: 10.2165/00002018-200023030-00003.
3
3 year simvastatin treatment and lens nuclear back scattering.三年辛伐他汀治疗与晶状体核背向散射
Br J Ophthalmol. 2000 May;84(5):512-6. doi: 10.1136/bjo.84.5.512.
4
Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.辛伐他汀对晶状体混浊进展无影响的随机安慰剂对照研究。牛津胆固醇研究组。
Br J Ophthalmol. 1995 Nov;79(11):996-1002. doi: 10.1136/bjo.79.11.996.